Trials / Completed
CompletedNCT00999401
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Cyclacel Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study of sequential administration of oral sapacitabine and oral Seliciclib in patients with advanced solid tumors.
Detailed description
The primary objective of this study is to determine the maximum tolerated dose (MTD) or recommended phase II doses of sapacitabine and seliciclib administered sequentially or concomitantly. The secondary objectives are to evaluate antitumor activity of this sequential or concomitant treatment and to explore the pharmacodynamic effect of this treatment in skin and peripheral blood mononuclear cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sapacitabine and seliciclib | sequential or concomitant administration of sapacitabine and seliciclib |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2019-07-16
- Completion
- 2019-08-13
- First posted
- 2009-10-21
- Last updated
- 2021-12-22
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00999401. Inclusion in this directory is not an endorsement.